Trial Profile
CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute biphenotypic leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 15 Nov 2021 Status changed from active, no longer recruiting to completed.
- 18 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 22 May 2019 Planned number of patients changed from 30 to 40.